- Home
- DSGN vs GALT Comparison
DSGN vs GALT Comparison
Compare DSGN & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- GALT
- Stock Information
- Founded
- DSGN 2017
- GALT 2000
- Country
- DSGN United States
- GALT United States
- Employees
- DSGN N/A
- GALT N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- GALT Health Care
- Exchange
- DSGN Nasdaq
- GALT Nasdaq
- Market Cap
- DSGN 208.9M
- GALT 232.3M
- IPO Year
- DSGN 2021
- GALT N/A
- Fundamental
- Price
- DSGN $7.14
- GALT $4.21
- Analyst Decision
- DSGN
- GALT Strong Buy
- Analyst Count
- DSGN 0
- GALT 3
- Target Price
- DSGN N/A
- GALT $6.00
- AVG Volume (30 Days)
- DSGN 189.7K
- GALT 353.0K
- Earning Date
- DSGN 11-06-2025
- GALT 11-12-2025
- Dividend Yield
- DSGN N/A
- GALT N/A
- EPS Growth
- DSGN N/A
- GALT N/A
- EPS
- DSGN N/A
- GALT N/A
- Revenue
- DSGN N/A
- GALT N/A
- Revenue This Year
- DSGN N/A
- GALT N/A
- Revenue Next Year
- DSGN N/A
- GALT N/A
- P/E Ratio
- DSGN N/A
- GALT N/A
- Revenue Growth
- DSGN N/A
- GALT N/A
- 52 Week Low
- DSGN $2.60
- GALT $0.73
- 52 Week High
- DSGN $7.77
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- DSGN 65.47
- GALT 45.16
- Support Level
- DSGN $5.98
- GALT $4.45
- Resistance Level
- DSGN $6.61
- GALT $5.06
- Average True Range (ATR)
- DSGN 0.38
- GALT 0.49
- MACD
- DSGN 0.04
- GALT -0.12
- Stochastic Oscillator
- DSGN 99.62
- GALT 5.31
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.